MentionFox
Home › Executive changes › Stoke Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Stoke Therapeutics, Inc. executive changes

Every leadership change Stoke Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named1
Latest filing2026-09-25

Stoke Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-25. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-09-25 · 8-K

Reported

(b) On September 22, 2026, Edward M. Kaye, M.D. notified the Board of Directors (the "Board") of Stoke Therapeutics, Inc. (the "Company") of his intent to resign as a Class III director of the Board, and as a member of the Research and Development Committee of the Board, effective September 23, 2026.
Filed 2026-04-07 · 8-K

Appointed: G. Clare Kahn, Director

(d) On April 3, 2026, the Board of Directors (the "Board") of Stoke Therapeutics, Inc. ("Stoke" or the "Company"), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective immediately, to fill the vacancy created by the increase in Board size.
Hiring for a seat like this?

Find people with the same kind of experience as the Director at Stoke Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Stoke Therapeutics, Inc.
Selling to Stoke Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Stoke Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Stoke Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Stoke Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/stoke-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Stoke Therapeutics, Inc. (STOK) executive changes: 2 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/stoke-therapeutics